Zanidatamab showed promise in the NeoZanHER phase 2 trial evaluating treatment in early-stage HER2-positive breast cancer prior to surgery. The study, published in Nature Communications, tested the next-generation antibody designed to attack the HER2 receptor through two mechanisms. The trial focused on preoperative (neoadjuvant) settings, where pathologic response and biomarker shifts can help inform later-stage development. The report frames the data as supportive of developing zanidatamab further in combinations or expanded disease settings. For HER2 product developers, the central challenge is maintaining durable efficacy while achieving meaningful responses without escalating toxicity. A pre-surgery program also provides a platform for translational work on tumor biology changes. As more data emerge, teams will likely focus on subgroup response patterns, safety, and how the antibody’s dual-binding approach translates into clinical outcomes.